← Back to Search

Anti-metabolites

GTX Chemoradiation for Pancreatic Cancer

Phase 2 & 3
Waitlist Available
Led By William Sherman, MD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No prior chemotherapy or radiation therapy.
Locally advanced disease determined by Endoscopic ultrasound, CT scan (chest/abdomen/pelvis with contrast), MRI scan (of abdomen with gadolinium) or PET scan.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will study the safety and efficacy of a combination of Gemcitabine, Capecitabine, and Docetaxel in patients with locally advanced pancreatic cancer.

Who is the study for?
This trial is for patients with locally advanced pancreatic cancer that can't be removed by surgery due to blood vessel involvement. Participants must not have had prior chemotherapy or radiation, and should be ineligible for other priority studies. They need to understand the treatment process and consent willingly, without any medical conditions barring them from surgery or chemo.Check my eligibility
What is being tested?
The study tests a chemotherapy regimen called GTX (gemcitabine, capecitabine, docetaxel) over six cycles of three weeks each. Depending on blood vessel involvement (venous only or arterial), some may also receive radiotherapy. Successful treatment could lead to surgical removal of remaining cancer.See study design
What are the potential side effects?
Potential side effects include nausea, fatigue, low blood cell counts leading to increased infection risk, liver function changes, kidney stress indicated by abnormal BUN/creatinine levels, and potential tissue damage at the infusion site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have not had chemotherapy or radiation therapy before.
Select...
My disease is advanced but hasn't spread far, confirmed by a scan.
Select...
My pancreatic cancer has been confirmed by a tissue test.
Select...
I don't have health issues that prevent surgery, radiation, or chemo.
Select...
My tumor cannot be surgically removed because it is too close to major blood vessels.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To determine the effect of neoadjuvant regimen of GTX on the 2-year disease free survival rate
Secondary outcome measures
To describe the effect of neoadjuvant GTX regimen on resectability for those with arterial involvement and those with venous involvement, separately

Trial Design

2Treatment groups
Experimental Treatment
Group I: Group IIExperimental Treatment1 Intervention
Patients with arterial involvement and may have venous involvement with tumor treated with 6 cycles of GTX, thenb GX/RT and then surgery
Group II: Group IExperimental Treatment1 Intervention
Patients with only venous involvement Treated with 6 cycles og GTX and then surgery

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,431 Previous Clinical Trials
2,460,767 Total Patients Enrolled
William Sherman, MDPrincipal InvestigatorColumbia University

Media Library

Capecitabine (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT01065870 — Phase 2 & 3
Pancreatic Cancer Research Study Groups: Group I, Group II
Pancreatic Cancer Clinical Trial 2023: Capecitabine Highlights & Side Effects. Trial Name: NCT01065870 — Phase 2 & 3
Capecitabine (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01065870 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any other ongoing trials that are testing the combination of Gemcitabine, capecitabine, and docetaxel before radiotherapy?

"As of right now, there are 1057 active studies for Gemcitabine, capecitabine, docetaxel followed by radiotherapy. Of these, 358 are in Phase 3. With several trials for Gemcitabine, capecitabine, docetaxel followed by radiotherapy running out of in Guangzhou, Guangdong, there are still a total of 53306 locations operating trials for Gemcitabine, capecitabine, docetaxel followed by radiotherapy."

Answered by AI

Are there any spots still open in this research project?

"This study is not actively recruiting patients at this moment. The listing was originally created on December 1st, 2009 and was most recently edited on January 27th, 2014. If you are looking for other studies, 594 trials for cancer of the pancreas and 1057 for Gemcitabine, capecitabine, docetaxel followed by radiotherapy are still admitting patients."

Answered by AI

What condition is the Gemcitabine, capecitabine, docetaxel followed by radiotherapy treatment most often used to improve?

"Gemcitabine, capecitabine, and docetaxel followed by radiotherapy is a common treatment for patients that have received adjuvant anthracycline-containing therapy. This treatment method is also effective for patients suffering from conditions such as head and soft tissue sarcoma, as well as colorectal carcinoma."

Answered by AI
~4 spots leftby Apr 2025